Abstract: The purpose of this study was to evaluate plasma levels of vasoactive factors which may play a role in the altered vascular tone of pulmonary circulation during hepatic failure. In the 85 patients with hepatic dysfunction studied we obtained: ET-1:0.66+/-0.30, 1.35+/-0.30, 1.73+/-0.41 fmol/ml; Big-ET-1:1.42+/-0.14, 1.91+/-0.22, 2.26+/-0.20 fmol/ml; NO: 58.3+/-2.91, 68.0+/-4.44, 72.12+/-8.73 mumol/l; AM:14.7+/-1.78, 18.9+/-1.70, 23.14+/-3.08 pmol/l; ANP:17.8+/-3.96, 20.7+/-4.66, 23.7+/-5.25 pg/ml; BNP:27.4+/-6.23, 49.0+/-17.7, 63.5+/-16.1 pg/ml; DNP:230.8+/-18.6, 287.3+/-19.6, 270.7+/-27.8 pg/ml for Child-Pugh class A n=20, class B n=36, class C n=29, respectively. The vasoactive peptide increase, associated with the progression of hepatic dysfunction, suggests that they may, by the way, contribute to circulatory and gas exchange modifications.
Hepatopulmonary syndrome and vasoactive factors
2003
Abstract
Abstract: The purpose of this study was to evaluate plasma levels of vasoactive factors which may play a role in the altered vascular tone of pulmonary circulation during hepatic failure. In the 85 patients with hepatic dysfunction studied we obtained: ET-1:0.66+/-0.30, 1.35+/-0.30, 1.73+/-0.41 fmol/ml; Big-ET-1:1.42+/-0.14, 1.91+/-0.22, 2.26+/-0.20 fmol/ml; NO: 58.3+/-2.91, 68.0+/-4.44, 72.12+/-8.73 mumol/l; AM:14.7+/-1.78, 18.9+/-1.70, 23.14+/-3.08 pmol/l; ANP:17.8+/-3.96, 20.7+/-4.66, 23.7+/-5.25 pg/ml; BNP:27.4+/-6.23, 49.0+/-17.7, 63.5+/-16.1 pg/ml; DNP:230.8+/-18.6, 287.3+/-19.6, 270.7+/-27.8 pg/ml for Child-Pugh class A n=20, class B n=36, class C n=29, respectively. The vasoactive peptide increase, associated with the progression of hepatic dysfunction, suggests that they may, by the way, contribute to circulatory and gas exchange modifications.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
